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SUMMARY
A 34-year-old 13-week pregnant woman presented with
hypertension refractory to medical therapy and on
workup was found to have a right adrenal mass. Due to
her persistent increased blood pressure she was advised
urinary vanillylmandelic acid (VMA) and its level was
raised. MRI of the abdomen showed a well-circumcised
lesion in the right adrenal of 3.0×2.5 cm suggestive of
pheochromocytoma. The patient was started on
antihypertensives including α-blockers and β-blockers
and planned for right open adrenalectomy.
Intraoperatively, blood pressure was raised up to
180/110 mm Hg on slight manipulation of adrenal gland
which was controlled with glyceryl-trinitrate and volatile
agents. Postoperatively urinary VMA decreased to normal
range and all antihypertensives were gradually stopped.
She had uneventful pregnancy and delivered vaginally.
This case report highlights the importance of surgical
management of pheochromocytoma in second trimester
of pregnancy to avoid catastrophic complications later in
pregnancy.

to refractory hypertension. Meanwhile, the patient
became pregnant.

INVESTIGATIONS
Owing to persistent increased blood pressure (BP)
she was advised urinary vanillylmandelic acid
(VMA) which was raised 30 mg/24 h (normal level
2–7 mg/24 h). Later the family physician advised
ultrasound which revealed an adrenal mass. She
had an MRI subsequently which conﬁrmed a wellcircumscibed lesion in the right adrenal mass of
3.0×2.5 cm suggestive of PCC (ﬁgures 1 and 2).

DIFFERENTIAL DIAGNOSIS
Hypertension during pregnancy is usually attributable to pre-eclampsia ( pregnancy-induced hypertension) or chronic hypertension but secondary
causes of hypertension should be considered in
patients refractory to medical therapy. These
include renal vascular hypertension, coarctation of
the aorta and adrenal causes of hypertension
(Cushing syndrome, Conn’s syndrome, PCC).

BACKGROUND
Pheochromocytoma (PCC) is a neuroendocrine
tumour of the adrenal medulla (originating in the
chromafﬁn cells). PCC is a very rare condition in
pregnancy and it carries signiﬁcant risks to the
mother as well as to the fetus. Therefore, PCC
should be considered as a possible cause of refractory hypertension in pregnancy and appropriate
investigations should be carried out. The diagnosis
can be established by measuring catecholamines
and metanephrines levels in the plasma (blood) or
through a 24-hour urine collection for VMA. The
tumour is generally localised by MRI during pregnancy. Deﬁnitive treatment of PCC is surgical but
initially it should be treated medically to control
blood pressure with α-adrenergic blockers, followed by β-blockers. In this case report PCC was
detected in the second trimester, and managed
successfully.

CASE PRESENTATION
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A 34-year pregnant woman was referred to our
clinic because of hypertension refractory to medical
therapy and right adrenal mass. She had two
normal deliveries before this pregnancy and had no
complications. She was diagnosed to have essential
hypertension when non-pregnant and was prescribed ACE inhibitor (enalapril 10 mg twice daily).
Calcium channel blocker and β-blocker (amlodipine
10 mg four times a day and atenolol 50 mg twice
daily) were later added by the family physician due
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TREATMENT
Soon after these diagnostic tests, the patient developed symptoms including sweating, ﬂushing and
chest pain with BP 200/120 mm Hg. Cardiac evaluation was performed including ECG and echocardiogram which revealed no abnormality. The
treatment was revised and phenoxybenzamine
10 mg thrice daily was initiated resulting in
adequate control of hypertension as well as symptoms. Obstetric examination and ultrasound of the
fetus showed a single alive fetus with normal fetal
growth parameters. Considering the risk of hypertension during pregnancy and the possibility of
aggravation during later stages of pregnancy we
decided to excise the mass. Surgical risk and risk to
fetus was discussed with the patient. Obstetrician
also agreed with the plan and counselled the
patient about the possible chances of miscarriage.
The patient was planned for adrenalectomy during
13th week of pregnancy.
The patient was admitted for right open adrenalectomy and started on progesterone pessaries
400 mg twice daily. Intraoperatively, BP raised to
180/110 mm Hg on slight manipulation of adrenal
gland which was controlled by the anaesthetist with
glyceryl-trinitrate and volatile agents included isoﬂurane and nitrous to control the BP during
surgery. Operative time was 160 min with a blood
loss of only 200 mL and without any need of transfusion. Postoperatively in the recovery room the
1
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Figure 1 Abdominal MRI (coronal
view) showing the right adrenal mass
(arrow).

obstetrician performed ultrasound and the fetal heart was
checked, which was found normal.
For pain management the anaesthetist started pethidine via
patient-controlled intravenous analgesia (PCIA). She was prescribed intravenous paracetamol and morphine after discontinuation of PCIA. The patient was kept in the intensive care unit
for labile BP for 2 days which was managed by ﬂuid resuscitation and adjustment of dosage of antihypertensives. The endocrinologist gradually tapered off the antihypertensive
medication over 3 days postoperatively. On second postoperative
day, slight per vaginal spotting was noticed which settled with
observation. The patient was discharged on seventh POD with
propranolol 10 mg twice daily and progesterone pessaries
400 mg twice daily.

OUTCOME AND FOLLOW-UP
The patient was followed up in the clinic after 2 weeks, she was
ﬁne with normal fetal growth parameters on ultrasound.
Urinary VMA decreased to normal range and all antihypertensives were stopped. She was followed up in the obstetric clinic,
had safe pregnancy and delivered vaginally at term.

Figure 2 Abdominal MRI (axial view) showing the right adrenal mass
(arrow).
2

DISCUSSION
PCC accounts for 0.1–1% of all cases of hypertension. Precise
incidence in pregnancy is difﬁcult to determine but more than
200 cases have been reported in the published literature. PCC
is a very rare neuroendocrine tumour which originates from
the adrenal medulla (chromafﬁn cells). This tumour is notorious for its devastating consequences.1 2 PCC is occasionally
referred to as ‘10% tumors’ because 10% are bilateral, 10%
are extra-adrenal and 10% are malignant.2 3 In pregnancy, the
presence of PCC may be difﬁcult to detect owing to the more
prevalent diagnosis of pregnancy-induced hypertension. It is
usually suspected when patient is not responding well to antihypertensives. Untreated PCC carries a risk of mortality for
the mother and the fetus, as high as 58%.4 5 Early diagnosis is
vital and symptoms and signs vary which includes: hypertension (98% of cases), orthostatic hypotension, palpitations,
tachycardia, headache, sweating, seizure disorders and anxiety
attacks. Other symptoms are chest pain, nausea and vomiting,
pallor and ﬂushing.2 6 Pregnancy does not alter urinary catecholamines hence diagnosis is conﬁrmed by 24 h urine VMA,
metanephrines or catecholamines. Metanephrines and catecholamines can be measured in the blood as well.7 8 In adults,
approximately 80% of PCC are unilateral and solitary. For
localisation ultrasound of the abdomen should be performed
as it is easily accessible, cheap and a safe modality in pregnancy and has 89–97% sensitivity. MR has the advantages of
greater accuracy, high-quality images and lack of ionising radiation.9–12 As the complication rate increases with progression
of pregnancy, late ﬁrst trimester and second trimester are the
ideal times for surgical treatment after organogenesis is completed. Surgery should be avoided in early ﬁrst trimester
because of high chances of miscarriage and in late second trimester and third trimester because of abdominal exploration
and access is difﬁcult.12 13
PCC should always be treated ﬁrst medically to stabilise the
BP and symptoms. α-Adrenoceptor blockade that is either phenoxybenzamine or prazosin and β-blockade is used to control
tachycardia and dysrhythmia.8 11 12 14 The aim of this pretreatment is twofold: ﬁrst, before undergoing surgery, blood
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pressure, heart rate and volume depletion should be restored
as far as possible. Second, the patient should be protected
from the toxic cardiovascular effects of preoperative surges of
catecholamines.1 15 The deﬁnitive treatment of PCC is surgical
excision either open, laparoscopic or robotic.4 13 A brief literature review showed that patients with PCC during pregnancy
were managed with one of the two approaches. First, medically
up to the end of pregnancy and then tumour excision along
with C section.2 16 17 This approach appears to be more suitable for patients who present late in pregnancy and/or
adequately manageable with antihypertensives. The second
approach is resection of PCC preferably during the second trimester. Robotic adrenalectomy during pregnancy has been
reported and the patient had no perioperative complication.13
Individualised management is appropriate as no single protocol
is suitable for all patients given the rarity and the complexity
of the problem.
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